Insulet has received a CE mark for the integration of its Omnipod 5 insulin pump and Abbott’s Freestyle Libre 2 Plus continuous glucose monitor (CGM) sensor.

The clearance positions Insulet to begin selling the integrated Type 1 diabetes product in Europe in the first half of 2024, starting with a phased launch in the United Kingdom and Netherlands.

Both companies have talked up the potential of insulin pump-CGM integration, with Insulet saying “there’s a huge open market” and Abbott calling it “a great opportunity” at recent investor events.